Multicenter, Randomized, Phase III Trial of CD8+ Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma

医学 肾切除术 肾细胞癌 养生 肿瘤浸润淋巴细胞 随机对照试验 胃肠病学 内科学 醛类白血病 CD8型 泌尿科 白细胞介素2 安慰剂 免疫疗法 外科 肾 病理 免疫学 细胞因子 癌症 抗原 替代医学
作者
Robert A. Figlin,John A. Thompson,Ronald M. Bukowski,Nicholas J. Vogelzang,Andrew C. Novick,Paul H. Lange,Gary D. Steinberg,Arie S. Belldegrun
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:17 (8): 2521-2521 被引量:233
标识
DOI:10.1200/jco.1999.17.8.2521
摘要

PURPOSE: To prospectively evaluate in a multicenter randomized trial the antitumor activity of CD8(+) tumor-infiltrating lymphocytes (TILs) in combination with low-dose recombinant interleukin-2 (rIL-2), compared with rIL-2 alone, after radical nephrectomy in metastatic renal cell carcinoma patients. PATIENTS AND METHODS: Between December 1994 and March 1997, 178 patients with resectable primary tumors were enrolled at 29 centers in the United States and Europe. Patients underwent total nephrectomy, recovered, and were randomized to receive either CD8(+) TILs (5 x 10(7) to 3 x 10(10) cells intravenously, day 1) plus rIL-2 (one to four cycles: 5 x 10(6) IU/m(2) by continuous infusion daily for 4 days per week for 4 weeks) (TIL/rIL-2 group) or placebo cell infusion plus rIL-2 (identical regimen) (rIL-2 control group). Primary tumor specimens were cultured at a central cell-processing center in serum-free medium containing rIL-2 to generate TILs. RESULTS: Of 178 enrolled patients, 160 were randomized (TIL/rIL-2 group, n = 81; rIL-2 control group, n = 79). Twenty randomized patients received no treatment after nephrectomy because of surgical complications (four patients), operative mortality (two patients), or ineligibility for rIL-2 therapy (14 patients). Among 72 patients eligible for TIL/rIL-2 therapy, 33 (41%) received no TIL therapy because of an insufficient number of viable cells. Intent-to-treat analysis demonstrated objective response rates of 9.9% v 11.4% and 1-year survival rates of 55% v 47% in the TIL/rIL-2 and rIL-2 control groups, respectively. The study was terminated early for lack of efficacy as determined by the Data Safety Monitoring Board. CONCLUSION: Treatment with CD8(+) TILs did not improve response rate or survival in patients treated with low-dose rIL-2 after nephrectomy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Jasper的应助被温白开采纳,获得10
1秒前
英俊的铭的应助被linlianhao采纳,获得10
1秒前
小马甲的应助被小懿采纳,获得10
2秒前
2秒前
9465426发布了新的文献求助30
2秒前
iceanbecky发布了新的文献求助10
3秒前
打打的应助被风清扬采纳,获得10
3秒前
任性玫瑰发布了新的文献求助10
3秒前
hmhu完成签到,获得积分10
4秒前
4秒前
欧耶完成签到,获得积分20
4秒前
4秒前
回望发布了新的文献求助10
4秒前
xiaofeixia完成签到 ,获得积分10
5秒前
answer答案完成签到,获得积分10
5秒前
稳稳完成签到,获得积分10
6秒前
56455完成签到,获得积分10
7秒前
iNk的应助被Fantaro采纳,获得10
7秒前
LJH发布了新的文献求助10
7秒前
Qiao发布了新的文献求助10
7秒前
keibinn完成签到 ,获得积分10
8秒前
额特别发布了新的文献求助10
8秒前
9秒前
9秒前
9秒前
David发布了新的文献求助10
9秒前
巧克力发布了新的文献求助10
10秒前
10秒前
DW的应助被细心的凡蕾采纳,获得10
10秒前
NexusExplorer的应助被别梦寒采纳,获得10
11秒前
清秀语蝶的应助被zsy采纳,获得10
11秒前
NexusExplorer的应助被Www采纳,获得10
12秒前
脑洞疼的应助被111采纳,获得10
12秒前
任性玫瑰完成签到,获得积分10
13秒前
小马甲的应助被欧耶采纳,获得10
13秒前
马莱板凳人完成签到 ,获得积分20
14秒前
Army616完成签到,获得积分10
15秒前
hhh发布了新的文献求助10
15秒前
jiejie发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067